Abstract
Since the finding of EGFR gene mutation in non-small cell lung cancer (NSCLC) 15 years ago, remarkable progress of precision medicine has been observed in this field. Due to the different ratio of EGFR-mutation positive patients among races, lots of important evidence regarding EGFR-mutation positive NSCLC has been built in East Asia studies. In addition, various driver oncogenes such as ALK and ROS1 were then identified and corresponding molecular-targeted drugs for these mutations have been developed. Best sequence of treatment by using these drugs is now being investigated. Furthermore, immune checkpoint inhibitors (ICI) were approved for the treatment of NSCLC. The results of clinical trials by monotherapy of ICI as well as Chemo/ICI combo have made us consider appropriate biomarkers for optimizing selection of NSCLC patients, especially those without driver oncogene mutation. Currently NSCLC is leading the way in the development of precision medicine in solid tumors and novel clinical questions are emerging day by day. In this symposium, we discuss the development of precision medicine in NSCLC from the point of Japanese view and introduce our challenge to establish new evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
